RecruitingEarly Phase 1

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

China12 participantsStarted 2026-01-28

Plain-language summary

The purpose of this study is to assess the safety, tolerability, and efficacy of AZD0120 in highly sensitized adult participants with ESKD awaiting kidney transplant-who, as assessed by investigators, are improbable desensitization through conventional treatments (e.g., plasmapheresis and immunoadsorption)- with or without living donors.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. FOCBP who are sexually active with a non-sterilized male partner must agree to use one highly effective method of birth control for at least 3 years post AZD0120 infusion. For FOCBP participants who receive LDC but not AZD0120, the contraception time lasts from enrollment until 12 months after the last dose of LDC. Cessation of contraception after this point should be discussed with a responsible physician.
✓. All FOCBP must have a negative serum pregnancy test result 3 days prior to enrollment at Screening.
✓. Must refrain from donating ova within 3 years post AZD0120 infusion.

What they're measuring

The incidence of treatment-related adverse events AE/SAE

Timeframe: Through study completion, an average of 3 years

Occurrence of DLTs.

Timeframe: Through study completion, an average of 3 years

Trial details

NCT IDNCT07350837

SponsorTongji Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Gang Chen

027-83662892 gchen@tjh.tjmu.edu.cn

View on ClinicalTrials.gov More Highly Sensitized Patients Awaiting Kidney Transplant trials